|Mr. Randall E. Woods||Pres, CEO & Director||537.28k||N/A||1952|
|Mr. Peter T. Slover||Chief Financial Officer||358.31k||N/A||1975|
|Dr. Allison J. Hulme||COO, Head of R&D and Director||529.73k||N/A||1963|
|Dr. Samuel R. Denmeade||Chief Scientific Officer & Member of the Scientific Advisory Board||N/A||N/A||N/A|
|Dr. James Joseph Beesley||Sr. Director of Investor Relations||N/A||N/A||1972|
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Sophiris Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.